Welcome to the e-CCO Library!

search
Search by: 
Year: Category: Sub Type:
DOP30: Multi-‘omics profiling in patients with quiescent Inflammatory Bowel Disease identifies biomarkers predicting relapse
Year: 2020
Source: ECCO'20 Vienna
Authors: Nynke Borren
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or pediatrician refer a patient for suspected IBD?
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Dan Turner
Created: Tuesday, 28 May 2019, 3:32 PM
Files: 1
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Tadakazu Hisamatsu
Created: Tuesday, 28 May 2019, 3:32 PM
Adalimumab, Anti-TNF agents, Thiopurines (AZA / MP), Disease activity indices, Mucosal healing
Files: 1
DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Claire Liefferinckx
Created: Tuesday, 28 May 2019, 3:32 PM
Ustekinumab, Real world data
Files: 1
DOP33: Stratification of patients for treatment with adalimumab by a combination of immune-profiling and in vivo efficacy studies in a novel mouse model of Ulcerative Colitis
Year: 2020
Source: ECCO'20 Vienna
Authors: Roswitha Gropp
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Marina Aloi
Created: Tuesday, 28 May 2019, 3:32 PM
Montreal Classification, Paediatric
Files: 1
DOP34: Transplantation of human intestine into the mouse: A novel platform for study of inflammatory enterocutaneous fistulas
Year: 2020
Source: ECCO'20 Vienna
Authors: Michael Scharl
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP35: Monitoring of mucosal T cells subsets under biotherapies in IBD: Responders exhibit a phenotype similar to healthy controls
Year: 2020
Source: ECCO'20 Vienna
Authors: Nassim Hammoudi
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP36: Gut microbial variations in patients with quiescent Crohns disease predict subsequent disease flare
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Yael Haberman
Created: Tuesday, 28 May 2019, 3:32 PM
Microbiota, Crohn’s disease, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Prognosis, Microbiota
Files: 1
DOP37: Neoplastic lesions outside diseased area in Inflammatory Bowel Disease patients: A National Cohort Study
Year: 2020
Source: ECCO'20 Vienna
Authors: Anneline Cremer
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single centre experience
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Bram Verstockt
Created: Tuesday, 28 May 2019, 3:32 PM
colonoscopy, Mucosal healing, Vedolizumab, Mucosal healing, Real world data, Mucosal healing
Files: 1
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Bram Verstockt
Created: Tuesday, 28 May 2019, 3:32 PM
Mucosal healing, Prognosis, Anti-TNF agents, Vedolizumab
Files: 1
DOP38: Prevalence of fatigue in a severe Inflammatory Bowel Disease cohort highly exposed to biologics
Year: 2020
Source: ECCO'20 Vienna
Authors: Claire Liefferinckx
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP39: Safety of Combination Biologic and Anti-Rejection Therapy Post-Liver Transplantation in Patients with Inflammatory Bowel Disease: London Ontario Experience
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Christopher Ma
Created: Tuesday, 28 May 2019, 3:32 PM
Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Ustekinumab, Vedolizumab, Sclerosing Cholangitis, IBD-associated cancer, Clostridium difficile, Colorectal cancer, CMV, IBD and malignancy, Mortality, Real world data, Patient reported outcomes
Files: 1
DOP39: The first prospective, mucticentre, randomised controlled trial on discontinuation of infliximab in Ulcerative Colitis in remission; endoscopic normalisation does not guarantee successful withdrawal
Year: 2020
Source: ECCO'20 Vienna
Authors: Taku Kobayashi
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP40: Does levels of concerns and expectations predict IBD disease status?
Year: 2020
Source: ECCO'20 Vienna
Authors: Valérie Pittet
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence study
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Antoine Meyer
Created: Tuesday, 28 May 2019, 3:32 PM
Anti-TNF agents, Biosimilars, Real world data
Files: 1
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studies
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Russell D Cohen
Created: Tuesday, 28 May 2019, 3:32 PM
Tofacitinib, JAK inhibitors, Ulcerative colitis
Files: 1
DOP41: Low grade dysplasia prognosis and predictive factors for advanced neoplasia progression in the 21st century – a large multi-centre retrospective cohort study
Year: 2020
Source: ECCO'20 Vienna
Authors: Misha Kabir
Created: Tuesday, 23 June 2020, 4:58 PM
Files: 1
DOP42: Dietary Therapies Induce Rapid Response and Remission in Active Paediatric Crohn’s Disease
Year: 2019
Source: ECCO'19 Copenhagen
Authors: Rotem Sigall-Boneh
Created: Tuesday, 28 May 2019, 3:32 PM
CRP and other serum biomarkers, Disease activity Indices, Dietary therapy, Exclusive enteral nutrition, Paediatric, Disease activity indices
Files: 1